With the U.S. Food and Drug Administration approving an increasing number of targeted therapies and hundreds more in late-stage oncology pipelines close behind, pharmaceutical companies are racing to bring cancer patients drugs tailored to the molecular profile of their tumors, otherwise known as precision medicine. Hitting the right target in precision medicine, however, is fraught […]
The post Precision Medicine: Getting Oncology Drug Development Right appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Precision Medicine: Getting Oncology Drug Development Right